

Resource Summary Report

Generated by RRID on Jul 28, 2026

PE anti-human CD8

RRID:AB_1953244

Type: Antibody

Proper Citation

BioLegend Cat# 344706, RRID:AB_1953244

Antibody Information

URL: http://antibodyregistry.org/AB_1953244

Proper Citation: BioLegend Cat# 344706, RRID:AB_1953244

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_1953244

Vendor: BioLegend

Catalog Number: 344706

Alternative Catalog Numbers: 344705

Record Creation Time: 20250820T014319+0000

Record Last Update: 20250820T114106+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human CD8.

No alerts have been found for PE anti-human CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Guo Y, et al. (2025) Monocytes from patients with myelodysplastic syndrome inhibit natural killer cell-mediated antitumor function through the CD200/CD200R pathway. *International immunopharmacology*, 152, 114394.

Zhou Z, et al. (2025) EGFR TKIs suppress MUC1 glycosylation through the PI3K/AKT/SP1/C1GALT1 pathway to enhance TnMUC1 CAR-T efficacy in EGFR-mutant NSCLC. *Cell reports. Medicine*, 6(7), 102199.

Wienke J, et al. (2024) Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy. *Cancer cell*, 42(2), 283.

Klysz DD, et al. (2024) Inosine induces stemness features in CAR-T cells and enhances potency. *Cancer cell*, 42(2), 266.

Wang S, et al. (2024) Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR Mutant Non-Small Cell Lung Cancer. *Cancer research*.

Ramil CP, et al. (2024) Extracellular vesicles released by cancer-associated fibroblast-induced myeloid-derived suppressor cells inhibit T-cell function. *Oncoimmunology*, 13(1), 2300882.

Liu Y, et al. (2024) IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects. *iScience*, 27(1), 108597.

Le Y, et al. (2024) VentX promotes tumor specific immunity and efficacy of immune checkpoint inhibitors. *iScience*, 27(1), 108731.

Woolsey C, et al. (2023) Recombinant vesicular stomatitis virus-vectored vaccine induces long-lasting immunity against Nipah virus disease. *The Journal of clinical investigation*, 133(3).

Egan H, et al. (2023) Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment. *Cell reports*, 42(5), 112475.

West EE, et al. (2023) Loss of CD4+ T cell-intrinsic arginase 1 accelerates Th1 response kinetics and reduces lung pathology during influenza infection. *Immunity*, 56(9), 2036.

Reuschl AK, et al. (2022) HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory T cells. *Cell reports*, 39(2), 110650.

Le Y, et al. (2022) NF- κ B-regulated VentX expression mediates tumoricidal effects of chemotherapeutics at noncytotoxic concentrations. *iScience*, 25(11), 105426.

Ding S, et al. (2022) Patient-derived micro-organospheres enable clinical precision oncology. *Cell stem cell*, 29(6), 905.

Pedersen TK, et al. (2022) The CD4+ T cell response to a commensal-derived epitope transitions from a tolerant to an inflammatory state in Crohn's disease. *Immunity*, 55(10), 1909.

Wang N, et al. (2021) Limited TCR repertoire and ENTPD1 dysregulation mark late-stage COVID-19. *iScience*, 24(10), 103205.

Crespo ÂC, et al. (2020) Decidual NK Cells Transfer Granulysin to Selectively Kill Bacteria in Trophoblasts. *Cell*, 182(5), 1125.

Liu Y, et al. (2018) Tumor-Repopulating Cells Induce PD-1 Expression in CD8+ T Cells by Transferring Kynurenine and AhR Activation. *Cancer cell*, 33(3), 480.